KR20190066033A - 담도암의 치료 방법 - Google Patents
담도암의 치료 방법 Download PDFInfo
- Publication number
- KR20190066033A KR20190066033A KR1020197012517A KR20197012517A KR20190066033A KR 20190066033 A KR20190066033 A KR 20190066033A KR 1020197012517 A KR1020197012517 A KR 1020197012517A KR 20197012517 A KR20197012517 A KR 20197012517A KR 20190066033 A KR20190066033 A KR 20190066033A
- Authority
- KR
- South Korea
- Prior art keywords
- albumin
- nanoparticles
- composition
- taxane
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405706P | 2016-10-07 | 2016-10-07 | |
| US62/405,706 | 2016-10-07 | ||
| PCT/US2017/055559 WO2018067943A1 (en) | 2016-10-07 | 2017-10-06 | Methods of treating biliary tract cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190066033A true KR20190066033A (ko) | 2019-06-12 |
Family
ID=61831977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197012517A Ceased KR20190066033A (ko) | 2016-10-07 | 2017-10-06 | 담도암의 치료 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200129469A1 (enExample) |
| EP (1) | EP3522887A4 (enExample) |
| JP (1) | JP2019529520A (enExample) |
| KR (1) | KR20190066033A (enExample) |
| AU (1) | AU2017340913A1 (enExample) |
| BR (1) | BR112019006329A2 (enExample) |
| CA (1) | CA3039582A1 (enExample) |
| MX (1) | MX2019003694A (enExample) |
| WO (1) | WO2018067943A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス, エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| KR20230124947A (ko) * | 2020-12-22 | 2023-08-28 | 사이토테릭스 인코포레이티드 | 담즙 전달 방법, 이에 사용하기 위한 조성물 및 키트 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2552438T3 (pl) * | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| EP3056201A1 (en) * | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| WO2012151562A1 (en) * | 2011-05-04 | 2012-11-08 | Intellikine, Llc | Combination pharmaceutical compositions and uses thereof |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20160101128A1 (en) * | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
-
2017
- 2017-10-06 AU AU2017340913A patent/AU2017340913A1/en not_active Abandoned
- 2017-10-06 BR BR112019006329A patent/BR112019006329A2/pt not_active Application Discontinuation
- 2017-10-06 WO PCT/US2017/055559 patent/WO2018067943A1/en not_active Ceased
- 2017-10-06 KR KR1020197012517A patent/KR20190066033A/ko not_active Ceased
- 2017-10-06 EP EP17859266.3A patent/EP3522887A4/en not_active Withdrawn
- 2017-10-06 CA CA3039582A patent/CA3039582A1/en not_active Abandoned
- 2017-10-06 JP JP2019518506A patent/JP2019529520A/ja active Pending
- 2017-10-06 US US16/338,900 patent/US20200129469A1/en not_active Abandoned
- 2017-10-06 MX MX2019003694A patent/MX2019003694A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3522887A1 (en) | 2019-08-14 |
| WO2018067943A1 (en) | 2018-04-12 |
| EP3522887A4 (en) | 2020-06-10 |
| CA3039582A1 (en) | 2018-04-12 |
| BR112019006329A2 (pt) | 2019-06-25 |
| MX2019003694A (es) | 2019-06-24 |
| JP2019529520A (ja) | 2019-10-17 |
| US20200129469A1 (en) | 2020-04-30 |
| AU2017340913A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10328031B2 (en) | Methods of treating pancreatic cancer | |
| AU2018200347B2 (en) | Methods of treatment of pancreatic cancer | |
| US20160374952A1 (en) | Methods of treatment of hepatocellular carcinoma | |
| JP2013527232A (ja) | 膀胱がんの処置方法 | |
| KR20150119177A (ko) | 흑색종을 치료하는 방법 | |
| KR20190066033A (ko) | 담도암의 치료 방법 | |
| HK40009403A (en) | Methods of treating pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |